Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Carlos Antonio Moura"'
Publikováno v:
JCR: Journal of Clinical Rheumatology.
Publikováno v:
Arthritis careresearch.
Publikováno v:
Arthritis Care & Research. 75:1383-1384
Publikováno v:
Seminars in arthritis and rheumatism. 52
Autor:
Carlos Geraldo Moura, Luiz Henrique de Assis, Viviane Torres, Carlos Antonio Moura, Fabiana Rosa Moura
Publikováno v:
Journal of clinical rheumatology : practical reports on rheumaticmusculoskeletal diseases. 27(8S)
Autor:
V H Gomes de Souza, C Geraldo Moura, J Neto, Carlos Antonio Moura, Mittermayer Barreto Santiago
Publikováno v:
Lupus. 26:204-207
The relationship between primary hematologic disease and rheumatologic manifestations is well known, especially acute lymphocytic leukemia, lymphomas, plasma cell dyscrasias and myelodysplastic syndrome (MDS). Currently, more has been described about
Autor:
Victor Nunes, Paulo Góes, Fabiana Santos Rosa, Luiz Henrique de Assis, Carlos Antonio Moura, Constança Margarida Sampaio Cruz, Ítalo Magalhães Gusmão
Publikováno v:
Case Reports in Dermatology, Vol 7, Iss 3, Pp 345-351 (2015)
Case Reports in Dermatology
Case Reports in Dermatology
Psoriasis is an autoimmune disease triggered by different conditions in genetically susceptible people. It is characterized by variable cutaneous manifestations including localized or disseminated pustules. Generalized pustular psoriasis (GPP) has tw
Publikováno v:
Annals of the Rheumatic Diseases. 81:e237-e237
After reading the article from Braaten et al ,1 we reinforce our idea that suspending checkpoint inhibitors (CPI) due to musculoskeletal symptoms, even if severe, may not always be a good alternative, since in addition to losing an option in the trea
Publikováno v:
Arthritis careresearch. 70(7)
Every time we discuss rheumatoid arthritis (RA), we talk about early diagnosis, treat-to-target therapy, cost-effectiveness between biological and non-biological therapies, the role of disease activity meters, and when and how a biological therapy sh